Dialysis services and products provider Fresenius Medical Care AG & Co. KGAA is extending its lead in the renal therapies market even further with its latest plan to acquire NxStage Medical Inc., the specialist in home hemodialysis technologies.
Under the terms of the agreement, Fresenius will pay $30 per share for NxStage, about a 30% premium over the latter's closing share price of $23.14 on Aug. 4, the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?